In patients with portopulmonary hypertension (n = 13) included in the 12-week randomized placebo-controlled PATENT-1 trial, riociguat was well tolerated and improved 6-min walking distance (6MWD), World Health Organization functional class (WHO FC), and other efficacy parameters; 6MWD and WHO FC improvements were sustained over two years in the open-label extension, PATENT-2.
- portal hypertension
- pulmonary arterial hypertension
- soluble guanylate cyclase stimulator
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine